AAAAAA

   
Results: 1-12 |
Results: 12

Authors: Paliard, X Doe, B Selby, MJ Hartog, K Lee, AY Burke, RL Walker, CM
Citation: X. Paliard et al., Induction of herpes simplex virus gB-specific cytotoxic T lymphocytes in TAP1-deficient mice by genetic immunization but not HSV infection, VIROLOGY, 282(1), 2001, pp. 56-64

Authors: Bard, F Cannon, C Barbour, R Burke, RL Games, D Grajeda, H Guido, T Hu, K Huang, JP Johnson-Wood, K Khan, K Kholodenko, D Lee, M Lieberburg, I Motter, R Nguyen, M Soriano, F Vasquez, N Weiss, K Welch, B Seubert, P Schenk, D Yednock, T
Citation: F. Bard et al., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimerdisease, NAT MED, 6(8), 2000, pp. 916-919

Authors: Marshall, GS Li, MT Stout, GG Louthan, MV Duliege, AM Burke, RL Hunt, LA
Citation: Gs. Marshall et al., Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients, VIRAL IMMUN, 13(3), 2000, pp. 329-341

Authors: Corey, L Langenberg, AGM Burke, RL Straus, S
Citation: L. Corey et al., Immunologic strategies for herpes vaccination - Reply, J AM MED A, 283(6), 2000, pp. 746-747

Authors: Kohl, S Charlebois, ED Sigouroudinia, M Goldbeck, C Hartog, K Sekulovich, RE Langenberg, AGM Burke, RL
Citation: S. Kohl et al., Limited antibody-dependent cellular cytotoxicity antibody response inducedby a herpes simplex virus type 2 subunit vaccine, J INFEC DIS, 181(1), 2000, pp. 335-339

Authors: O'Hagan, D Goldbeck, C Ugozzoli, M Ott, G Burke, RL
Citation: D. O'Hagan et al., Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs, VACCINE, 17(18), 1999, pp. 2229-2236

Authors: Corey, L Langenberg, AGM Ashley, R Sekulovich, RE Izu, AE Douglas, JM Handsfield, HH Warren, T Marr, L Tyring, S DiCarlo, R Adimora, AA Leone, P Dekker, CL Burke, RL Leong, WP Straus, SE
Citation: L. Corey et al., Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials, J AM MED A, 282(4), 1999, pp. 331-340

Authors: Schmid, DS Brown, DR Nisenbaum, R Burke, RL Alexander, D Ashley, R Pellett, PE Reeves, WC
Citation: Ds. Schmid et al., Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2, J CLIN MICR, 37(2), 1999, pp. 376-379

Authors: McFarland, W Gwanzura, L Bassett, MT Machekano, R Latif, AS Ley, C Parsonnet, J Burke, RL Katzenstein, D
Citation: W. Mcfarland et al., Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers, J INFEC DIS, 180(5), 1999, pp. 1459-1465

Authors: Frey, SE Harrison, C Pass, RF Yang, E Boken, D Sekulovich, RE Percell, S Izu, AE Hirabayashi, S Burke, RL Duliege, AM
Citation: Se. Frey et al., Effects of antigen dose and immunization regimens on antibody responses toa cytomegalovirus glycoprotein B subunit vaccine, J INFEC DIS, 180(5), 1999, pp. 1700-1703

Authors: Pass, RF Duliege, AM Boppana, S Sekulovich, R Percell, S Britt, W Burke, RL
Citation: Rf. Pass et al., A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant, J INFEC DIS, 180(4), 1999, pp. 970-975

Authors: Nesburn, AB Burke, RL Ghiasi, H Slanina, SM Wechsler, SL
Citation: Ab. Nesburn et al., Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A thansystemic vaccination and provides protection against recurrent spontaneousocular shedding of virus in latently infected rabbits, VIROLOGY, 252(1), 1998, pp. 200-209
Risultati: 1-12 |